163 related articles for article (PubMed ID: 36535758)
1. [Not Available].
Delaye M; Lièvre A; Neuzillet C
Bull Cancer; 2022 Nov; 109(11S):11S11-11S20. PubMed ID: 36535758
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
3. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG
Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
Hack SP; Zhu AX
Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
[TBL] [Abstract][Full Text] [Related]
6. [Advance in immunotherapy on biliary tract cancers].
Liu LG; Zhang YJ; Wang XA; Liu YB
Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):156-160. PubMed ID: 33378809
[TBL] [Abstract][Full Text] [Related]
7. The role of novel biologics in biliary cancers.
Jordan E; Braghiroli MF; Lowery MA
Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
[TBL] [Abstract][Full Text] [Related]
8. [Biliary tract cancers: new medical therapeutic approaches guided by molecular data].
Delaye M; Neuzillet C
Ann Pathol; 2022 Dec; 42(6S):6S8-6S10. PubMed ID: 36577542
[No Abstract] [Full Text] [Related]
9. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
11. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
12. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
13. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
15. Current Progress in Immunotherapy for the Treatment of Biliary Cancers.
Pauff JM; Goff LW
J Gastrointest Cancer; 2016 Dec; 47(4):351-357. PubMed ID: 27538880
[TBL] [Abstract][Full Text] [Related]
16. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
Brandi G; Rizzo A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142781
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
18. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
19. Current progress in systemic therapy for biliary tract cancers.
Sutherland M; Ahmed O; Zaidi A; Ahmed S
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1094-1107. PubMed ID: 33735541
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
